The evolving proteome of SARS-CoV-2 predominantly uses mutation combination strategy for survival by Patro, L. Ponoop Prasad et al.
Computational and Structural Biotechnology Journal 19 (2021) 3864–3875journal homepage: www.elsevier .com/locate /csbjThe evolving proteome of SARS-CoV-2 predominantly uses mutation
combination strategy for survivalhttps://doi.org/10.1016/j.csbj.2021.05.054
2001-0370/ 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author.
E-mail address: tr@bt.iith.ac.in (T. Rathinavelan).
1 These authors contribute equally.L. Ponoop Prasad Patro 1, Chakkarai Sathyaseelan 1, Patil Pranita Uttamrao 1,
Thenmalarchelvi Rathinavelan ⇑
Department of Biotechnology, Indian Institute of Technology, Hyderabad Kandi Campus, Telangana State 502285, India
a r t i c l e i n f o a b s t r a c tArticle history:
Received 25 March 2021
Received in revised form 29 May 2021
Accepted 30 May 2021






Evolutionary dynamicsThe knowledge of SARS-CoV-2 proteome variations is important to understand its evolutionary tactics
and to design drug/vaccine. An extensive analysis of 125,746 whole proteome reveals 7915 recurring
mutations (involving 5146 positions) during December 2019-November 2020. Among these, 10 and 51
are highly and moderately recurring mutations respectively. Ever since the pandemic outbreak, 50%
new proteome variants evolve every month, resulting in 5 major clades. Intriguingly, 70% of the variants
reported in January 2020 are due to the emergence of mutations, which sharply declines to 40% in April
2020 and thenceforth, declines steadily till November 2020 (10%). An exactly opposite trend is seen for
variants evolved with a cocktail of existing mutations: the lowest in January 2020 (20%) and the highest
in November 2020 (80%). This leads to a steady increase in the average number of mutations per
sequence. This indicates that the virus has reached the slow pace to accept new mutations. Instead, it
uses a mutation combination strategy for survival.
 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
The SARS-CoV-2 pandemic is wreaking havoc worldwide by
infecting over 87 million people with a mortality of more than 1
million as on January 7, 2021 (https://www.worldometers.
info/coronavirus/). Although multiple factors such as age [1],
weather [2], health profile [3,4] etc. play an important role in caus-
ing the infection, the evolution in the viral genome/proteome is yet
another major concern. Indeed, independently emerged SARS-CoV-
2 variants in UK (VUI 202012/01 (B.1.1.7)), South Africa (501Y.V2
(B.1.351)), Brazil (P.1 (B.1.1.28.1)) and Uganda (A.23.1) [5] are
suggested to be more transmissible compared with the existing
variants [6]. SARS-CoV-2, a positive stranded RNA virus (30 kb
size), is equipped with 10 open reading frames (ORFs) which are
translated into 26 proteins that are vital for its adaptation and
survival. Although the virus is equipped with a sophisticated proof-
reading mechanism, an earlier investigation has identified the
existence of 9 and 27 high and moderate recurrent mutations
respectively across the globe until May 2020 [7]. Among these,
D614G mutation in the spike protein has now conquered the wildtype and has proven to enhance the viral fitness and transmissibil-
ity [8,9].
As many western countries have already reached the second
wave of SARS-CoV-2 infections and started implementing the sec-
ond phase of lockdown [10], it is important to understand the viral
evolution to aid in the development of successful antiviral therapy
for the prevention and treatment of the infection. To this end, the
variations acquired by SARS-CoV-2 proteome have been investi-
gated by analyzing 125,746 whole proteome sequences [collected
until November 2020 and deposited in GISAID (https://www.gi-
said.org) on or before December 10, 2020 [11]] obtained from
121 countries (See Materials and methods for details, Table S1).
The analysis reveals that SARS-CoV-2 has explored 7915 recurring
(occurs in at least 3 out of 125,746 sequences) mutations during
December 2019-November 2020. Among them, 10 are highly
recurring mutations (percentage frequency (PF) more than 10%)
and have been explored by SARS-CoV-2 during the pre-lockdown
period. By using these mutations, SARS-CoV-2 has evolved into 5
major clades and their 6 sub-clades during December 2019-
November 2020. Further, 51 mutations recur at a moderate per-
centage (between 1 and 10%) and the rest of them occur below
1%. Interestingly, the evolution of SARS-CoV-2 proteome with
new mutations is in declining phase after March 2020, whereas,
the proteome with a cocktail of existing mutations (henceforth,
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the virus would already have explored majority of the favorable
mutations and thus, continues its evolution using a cocktail of
existing mutations.
2. Results
To understand the viral evolution strategy, the mutations
acquired by the SARS-CoV-2 proteome during December 2019 to
November 2020 have been analyzed and are discussed below.
2.1. Pre-lockdown emergence of 10 highly recurring SARS-CoV-2
mutations
The analysis of 125,746 proteome sequences have revealed that
until November 2020, 7326 amino acid positions of 26 SARS-CoV-2
proteins have undergone changes 15,369 times (Table S2). Among
these, 7915 mutations are found to occur in more than 3 sequences
(viz., percentage frequency above 0.002%). Spike:D614G, Nsp12:
P323L, N protein:R203K-G204R, ORF3a protein:Q57H, Nsp2:T85I,
Spike:A222V, ORF10 protein:V30L, N protein:A220V and Spike:
L18F are the 10 highly recurring (HR) mutations whose overall per-
centage frequency (PF) is greater than 10% during December 2019
to November 2020. Among these, the spike protein D614G muta-
tion, which has emerged in early January 2020, has surged to
nearly 100% in the month of November 2020 (Fig. 1A). Nsp12:
P323L, which occurs most of the time along with Spike:D614G,
has also attained 100% PF during November 2020 (Fig. 1A &
Fig. S1). Intriguingly, the virus has tried this combination in China
during the very early stage of pandemic (Fig. 2, Table S3) (GISAID
ID: EPI_ISL_422425, January 2020, Table S4). Subsequently, this
combination is seen in more than 60% of the SARS-CoV-2
sequences that are collected until March 2020 (Fig. 1A) [8].
However, Germany has reported the first independent occurrence
of D614G during early January 2020 (GISAID ID: EPI_ISL_406862,
Table S4). Followed by these, the N protein co-mutations (N pro-
tein: R203K-G204R) occur with a PF of 33% since its first emer-
gence in UK in February 2020 (Fig. 1A & Fig. 2) (GISAID ID:
EPI_ISL_466615). Similarly, ORF3a protein:Q57H and Nsp2:T85I
have occurred for the first time in Saudi Arabia (EPI_ISL_489996)
and France (EPI_ISL_418218) respectively in February 2020
(Fig. 2 & Table S3). Although they occur with PF greater than 10%
during the entire pandemic period, their occurrence has reduced
significantly after June 2020.
Unlike the above mutations, which occur (with the overall PF)
above 10% even during pre-lockdown period, the hydrophobic trio
mutations N protein:A220V, ORF10 protein:V30L and Spike:A222V
have picked up only from August 2020 (Fig. 1A) even though they
are first seen in Tunisia in March 2020 along with Spike:D614G and
Nsp12:P323L (EPI_ISL_683329). They have started spreading
widely in Europe from August 2020 with a PF of 11% and increased
steeply and has attained the percentage frequency of 70% in
November 2020 (Fig. 1A). Note that their individual appearances
are also seen in Europe: N protein:A220V in Portugal
(EPI_ISL_511521), ORF10 protein:V30L in Denmark
(EPI_ISL_444822) and Spike:A222V in Spain (EPI_ISL_467173).
Similarly, Spike:L18F occurs with a high recurrence after Septem-
ber 2020 (with an overall PF of 12%) (Fig. 1A), although it has
appeared for the first time in March 2020 in Iceland
(EPI_ISL_417765).
In contrast to above, Nsp6:L37F, which occurs with a high
recurrence during the early stage of the pandemic sustains only
at a moderate recurrence after March 2020 (Fig. 1B). A similar
trend is observed for ORF8 protein:L84S and ORF3a protein:
G251V, which have a high recurrence before March 2020, but have
subsequently reached the declining phase (Fig. 1B). Surprisingly,3865the surging time period of Spike:D614G and Nsp12:P323L muta-
tions overlaps with the diminishing period of ORF8 protein:L84S
and ORF3a protein:G251V (Fig. 1C). Strikingly, ORF8 protein:L84S
is one of the two characteristics mutations of the SARS-CoV-2 lin-
eage A [12]. Even though ORF8 protein:L84S (GISAID ID:
EPI_ISL_412982) and ORF3a protein:G251V (EPI_ISL_447919) have
occurred along with Spike:D614G and Nsp12:P323L during Febru-
ary 2020, they are rarely seen together. This suggestive of evolu-
tionary disadvantage of Spike:D614G and Nsp12:P323L occurring
in lineage A or vice-a-versa and ORF3a protein:G251V of lineage
B occurring together with Spike:D614G and Nsp12:P323L.
Fig. 2 summarizes the pre-lockdown (https://www.bbc.com/
news/world-52103747) emergence, dissemination and surge of
the 10 highly recurring mutations of SARS-CoV-2 proteome.
2.2. Highly recurring mutations in the non-coding regions
The changes in the SARS-CoV-2 genome have also been exam-
ined. The results indicate that 19,270 nucleotide positions have
undergone changes 27,200 times during the evolution. More
specifically, the 6 non-coding regions of SARS-CoV-2 genome,
namely, 50UTR, ORF1ab stemloop 1&2, ORF10 stemloop 1&2 and
30UTR have exhibited 1,124 variations (Table S5). Out of those,
632 mutations are occurring at least thrice (PF above 0.002%).
Notably, C241T (PF = 92%) of 50UTR mostly occurs along with
Spike:D614G and Nsp12:P323L (Fig. 1A & 1D) although it has been
found to occur independently in some incidences. The three muta-
tions are first seen together in China in January 2020
(EPI_ISL_451345). Other highly recurring mutations in the non-
coding regions are G204T in 50 UTR and G29645T in ORF10 stem-
loop 2 (an equivalent of ORF10 protein:V30L), which are on the sig-
nificant rise from August 2020 with an overall PF of 14% and 23.7%
respectively (Fig. 1D).
2.3. Emergence of moderately recurring 51 proteome mutations and 4
non-coding region mutations
In addition to the above-discussed proteome mutations, 51
variations (including substitutions and deletions, Fig. S2) are found
to occur with a moderate percentage frequency (between 1 and
10%) (Table S2). Interestingly, 45 of them have their first incidences
before March 2020 (Fig. S2 & Table S3), while the remaining 6
mutations (N protein:A376T, Nsp13:K218R, Nsp12:E254D,
Nsp12:A656S, Nsp9:M101I and Nsp12:V720I) have emerged after
April 2020. Among these, 13, 33 and 5 are present in the structural,
non-structural and accessory proteins respectively.
It is noteworthy that following moderately recurring mutations
co-occur with the overall PF more than 3% (Table S2): Nsp12:V720I
& Nsp9:M101I and Nsp12:A185S, Nsp12:V776L, N protein:A376T
& Nsp13:K218R. Among them, N protein:S194L which has emerged
in China in January 2020 (EPI_ISL_406594) appears steadily after
April 2020 and has an overall PF of 5.66% (the highest among the
moderately recurring mutations). Markedly, Nsp13:Y541C,
Nsp13:P504L, ORF8 protein:L84S and ORF3a protein: G251V have
vanished after August 2020 (PF = 0% after August 2020). Other
notable mutations are Spike:H69- and Spike:V70- deletions.
Besides, 7854 recurrent mutations (among them, 492 mutations
are occurring with PF 0.1–1%) have been observed until November
2020 (PF in the range of 0.002 to 1%) (Table S2). Among these,
Spike:E583D, Spike:P272L, Nsp3:T1189I, Nsp2:A318V, Nsp5AB:
K90R, Spike:S98F, ORF3a protein:V202L, ORF8 protein:A65V,
Nsp15:K12R, N protein:H145Y, Spike:S256L, Nsp3:H295Y, Spike:
D215H, ORF3a protein:Q38R, Nsp6:V149F, ORF3a protein:G172R,
Spike:D1163Y, N protein:P13T, Spike:A688V, Spike:G1167V, N pro-
tein:Q9H, Nsp15:T114A, Nsp16:R216C, ORF3a protein:G172V,
ORF3a protein:V163I, Nsp3:S126L, Nsp12:T76I and Nsp14:N129D
Fig. 1. Month wise occurrence of key recurrent SARS-CoV-2 mutations. (A) Month wise occurrence of top 10 recurrent SARS-CoV-2 mutations. (A: Last column) Emergence of
highly recurring (HR) mutations that occur after August 2020. Note that the emergence of N protein: A220V, ORF10 protein: V30L, Spike:A222V and Spike:L18F is seen only
after July 2020. (B) Decrease in the percentage frequency of some of the mutations which were highly recurring before March 2020. Note that the occurrence of ORF8 protein:
L84S and ORF3a protein: G251V are completely reduced after May 2020 and the occurrence of Nsp6:L37F is reduced from HR to moderate recurrence (MR) after March 2020.
(C) Diagram illustrating the rise (before Spike: D614G becomes dominant) and fall (after Spike:D614G takes over the wild type) of ORF8 protein:L84S and ORF3a protein:
G251V. (D) Emergence of non-coding region mutations with a high recurrence (HR). Note that 50UTR:C241T mutation has started occurring after February 2020 and 50UTR:
G204T and ORF10 stemloop: G29645T mutations have started occurring after August 2020.
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Fig. 2. Diagram illustrating (A) the date of first incidence corresponding to 10 highly recurring mutations in 121 countries considered in the current investigation and (B) the
persistence of recurring mutations. A) The countries are number coded (refer to the numbers below Fig. 2A) and are indicated in the X–axis. The circles around the dot
indicate the country which first acquires any of the 10 HR mutations (differentiated by colors). (B) Pie chart elucidating (Left) month wise mutation persistence (viz.,mutation
emerged in a month (December 2019-September 2020) and have persisted in October 2020 or November 2020) and (Right) protein wise mutation persistence (viz.,mutations
emerged in a protein any time during December 2019-September 2020 and have persisted in October 2020 or November 2020). See Materials and methods for details. (For
interpretation of the references to color in this Figure legend, the reader is referred to the web version of this article.)
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ber or October or November 2020 onwards. Notably, 8 of them
are the Spike protein mutations.
In the non-coding region, C13536T in ORF1ab stemloop 2
(PF = 1.58%), G29734C (PF = 2.2%) and A29771G (PF = 1.8%) in
30UTR and C66T in 50UTR (PF = 1.76%) are moderately recurring
mutations. Among these, the 30UTR mutations are steadily rising
from August 2020.2.4. Lineage A specific mutations
It is well known that SARS-CoV-2 lineage A and lineage B differ
from each other due to presence of ORF8 protein:L84S and a silent3867mutation C8782T in the former [12]. Interestingly, none of the lin-
eage A mutations are found either in high or moderate percentage
frequency. Nevertheless, 42 mutations (PF in the range of 0.38–
0.002%) are found to be specific for lineage A (Table S6 and
Table S4) and they occur very rarely in lineage B.2.5. Mutation persistence
The mutation persistence analyses (see Materials and methods)
indicate that among the 15,369 mutations, 5,361 occur persistently
during the time period considered here. Among them, 63% have
emerged inMarch 2020 and April 2020 (Fig. 2B (Left)). This supports
the early emergence of not only most of the high and moderate
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mutations. To our surprise, Nsp3 owns the highest persistent muta-
tions (19%) followed by the spike protein (12.8%) (Fig. 2B (Right)).
The other proteins that have more than 5% of the persistent muta-
tions are: Nsp2 > N protein > Nsp12 > ORF3a protein. Six proteins
have persistent mutations less than 1%: ORF6 protein > ORF7b pro-
tein > E protein Nsp10 > Nsp7 > ORF10 protein.2.6. Decline in the emergence of mutations and escalation in the
cocktail of existing mutations post-lockdown
Comparative SARS-CoV-2 whole proteome analysis reports that
the number of proteome variants per month follows the same
trend as the number of sequences collected in a particular month
(Fig. 3A). March 2020, April 2020 and November 2020 are the
top 3 months that have more number of sequences with a cocktail
of mutations (viz., variants) (Fig. 3A & Table S7). More than 50% of
the total number of variants seen every month are found to be new
(Fig. 3A, 3B & Table S7). The remaining variants are identical to the
proteome variants reported in the previous month(s) (Fig. 3B).
Detailed analysis indicates that the new proteome variants differ
from the existing proteome variants in one or more amino acid
positions. Surprisingly, segregation (Fig. 3C) of the frequency of
occurrence of new proteome variants into proteome variants with
a newly emerged mutation(s) and with the cocktail of existing
mutations indicates that during February 2020 the evolution of
variants with new mutations is at the highest frequency (80%)
which sharply declines after April 2020 (50%). Subsequently, it
has entered into a steady declining phase and has reached a fre-
quency of 20% in November 2020. An exactly opposite behavior
has been seen in the emergence of variants with the cocktail of
existing mutations: the lowest in January 2020 (20%) and a sharp
surge till April 2020 (60%) which is followed by a steady growth
every month (80%) (Fig. 3C). As the result, there is a steady
increase in the average number of mutations per sequence: nearly
0 in December 2019 and 9 in November 2020 (Fig. 3D). Indeed, a
proteome variant with the bevy of 24 mutations is found in August
2020 indicating the flexibility in the viral proteome to accommo-
date a greater number of mutations (EPI_ISI 570600, USA). Thus,
it indicates that after examining the suitable mutations during
the early stage of the pandemic, the virus now tests their cocktail
to continue its survival (Figs. 2, 3, Table S2, Table S7, and Table S8).2.7. Distribution and persistence of SARS-CoV-2 proteome variants
A total of 43,499 SARS-CoV-2 proteome variants have been
identified until November 2020 (Fig. 3E) and UK has the highest
number of variants with a cocktail of mutations (19084, Fig. 3I).
However, only 197 variants appear at least in 50 sequences
(Fig. 3E & 3F). Among them, 5, 6, 78 and 100 variants are seen at
least in 1000 (Fig. 3F & 3G), 500 to 999 (Fig. 3F & 3G), 100 to 499
and 50 to 99 sequences respectively (Fig. 3F). Interestingly, only
760 variants persist during October 2020 and November 2020
(Fig. S3). Not surprisingly, unlike the case of individual mutations
(Fig. 2B (Left)), the variants that have emerged in August 2020
(549 variants) and September 2020 (131 variants) persisted during
October 2020 and November 2020 compared with the variants that
have emerged in the previous months (Fig. S3). The Spike, Nsp12
and N protein have contributed to above 70% of the variants
(Fig. 3H). Nsp10, ORF6 protein and E protein have taken the last
3 places in terms of variant contribution.38682.8. Suppression of clade 1 and clade 2 by spike:D614G and Nsp12:
P323L
Throughout the progression of the pandemic, there has been a
lot of dynamics in the proteome of the SARS-CoV-2. To understand
the dynamics in the SARS-CoV-2 proteome, phylogenetic trees
have been constructed using the SARS-CoV-2 proteome sequences.
Prior to the phylogenetic tree construction, a multiple sequence
alignment has been carried out (as mentioned in the Materials
and methods section) and subjected to phyloproteomic tree con-
struction. Since phyloproteomic tree construction depends on the
probability of the amino acid(s) mutation, it will reflect in the clus-
tering of sequences with similar mutation(s) leading to a new
clade/sub-clade. The results indicate the dominance of wild-type
proteome in December 2019, which declines drastically to 2.8%
in February 2020, followed by 0% occurrence in the following
months (Fig. S4). Not surprisingly, the highly recurring mutations
reported in Fig. 1A above have led to 5 major clades as reported
earlier [7]. For instance, due to D614G (highly recurring) mutation,
there is an emergence of a clade (indicated in Fig. 4A as Spike:
D614G, clade-3a). Similarly, other amino acids responsible for the
emergence of a proteome clade or sub-clade have been indicated
in Fig. 4A. Nonetheless, soon after the surge of Spike:D614G
(clade-3a) and Nsp12:P323L (clade-4) (Fig. 4A & 4B), 4 major
sub-clades have evolved during May 2020 (Fig. 4B & Fig. S5B):
clade-3b (Spike:D614G and Nsp12:P323L), clade-3c (Spike:
D614G, Nsp12:P323L, ORF3a protein:Q57H), clade-3d (Spike:
D614G, Nsp12:P323L, ORF3a protein:Q57H, Nsp2:T85I) and
clade-3e (Spike:D614G, Nsp12:P323L, N protein:R203K and N pro-
tein:G204R. Yet another branching in clade-3b takes place in
August 2020 due to the emergence of N protein:A220V, ORF10 pro-
tein:V30L and Spike:A222V trio mutations (clade-3f). Conse-
quently, merging of these clades/sub-clades (clades 3c, 3d, 3e, 3f
and 1a) takes place as the virus evolves. Fig. 4B & Fig. S5 show
the month wise dissemination of these clades as Spike:D614G
(clade-3a) and Nsp12:P323L dominate the world (Fig. 4B, Fig. S5
& Fig. 1A) (Table S9). It is noteworthy that the clade-5 doesn’t have
any high recurrent mutations. Intriguingly, the clades 1b (Nsp6:
L37F and ORF3aprotein:G251V) and 2 (ORF8 protein:L84S) vanish
as ORF3a protein:G251V and ORF8 protein:L84S mutations decline
steeply along with the rise of Spike:D614G and Nsp12:P323L
(Fig. 4B & Table S9) (Fig. 1A, 1B & 1C). However, the merging of
clade 2 (ORF8 protein:L84S) and clade 1b (ORF3a protein:G251V)
with clade 3 (Spike:D614G) is seen to occur very rarely, suggesting
the fitness disadvantage for the virus.
Further analysis indicates that some of the clades are found
only in certain countries, as given in Fig. 4C & Fig. S5 (Table S10).
For instance, the clade-3e and clade-3f are majorly found in the
European countries. Similarly, the following clades are found to
be dominant in certain countries (during the overall time period
considered in this study) clade-3d in USA, clade-1a in Singapore,
clade-3e in Australia (92%), clade-1a-3e (merger of clades 1a and
3e) in Jordan and clade-3b in Mexico. Interestingly, the Spike:
D614G clade or its mergers are found in less percentage in China
which can be attributed to a smaller number of sequences depos-
ited after March 2020 (after which the Spike:D614G has slowly
overtaken the wild-type). The emergence of highly recurring trio
mutations (N protein:A220V, ORF10 protein:V30L and Spike:
A222V) in Europe and their merging with Spike:D614G and
Nsp12:P323L (clade-3b) has led to a new sub-clade-3f. Our study
further highlights that the origin of clade-3f (one of the widely
spread proteome variants in Europe and is also confined to Euro-
pean nations) is Tunisia, Africa (EPI_ISL_683329, March 2020)
which is so far believed to be originated from Spain (July 2020)
[13].
Fig. 3. (A-D) Month wise summary of SARS-CoV-2 proteome variant distribution (December 2019 to November 2020) and (E-H) their persistence. (A) Line plot illustrating
number of unique proteome variants (deep red color) present in the total number of sequences collected (blue color) in a particular month. (B) Month wise percentage
frequency (%) of appearance of new variants (colored dark blue) and preexisting variants (colored red). (C) Line plot illustrating the month wise emergence of proteome
variants with newly emerged mutations (purple color) or with cocktail of existing mutations only (pink color). (D) Box plot elucidating the month wise occurrence of single
amino acid mutations in SARS-CoV-2 sequences (December 2019 to November 2020). Note that the average number of mutations linearly increases every month in the SARS-
CoV-2 proteome. Due to the availability of less number of sequences in December 2019, the data is indicated by ‘‘*” in Fig. 3A–C. (E-G) Relative percentage of occurrence of
variants that are found at least 3 (E), 50 (F) and 500 (G) times. (H) Bar chart representing the protein wise variant distribution. (I) Country wise distribution of SARS-CoV2
variants. Note that the variant counts have been indicated for the top 5 countries. (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
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Fig. 4. SARS-CoV-2 proteome clades and their dissemination. (A) SARS-CoV-2 proteome clade (CL) definition based on highly recurring (HR) mutations. (B) Month wise and
(C) country wise distribution of top 10 clades of SARS-CoV-2 and their mergers. Note that (B) Clade-3e (light green color) is highly distributed during March 2020 to August
2020 and declines thenceforth, whereas clade-3f (violet color) is highly distributed after August 2020. (C) The clade-3f (violet color) is highly distributed in European
countries and clade-3e (light green color) is distributed almost in all the countries. (D) Month wise percentage occurrence of top 10 clades. Note the steady increase in clade-
3f from August 2020. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 5. Month wise evolutionary dynamics of clade-3d (CL-3d) showing the divergence of the sub-clades from its ancestors. The month (X-axis) of first emergence to the
month of last appearance of a sub-clade in a particular country is represented by a bar. The amino acid variations are given in the Y-axis. The country of first incidence is
mentioned alongside the bar. The magenta colored star indicates that the sub-clade is country specific. PV number indicates the protein variant number of the particular sub-
clade (refer Table S8). Note that only top 25 sub-clades are shown here. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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of existing mutations
Among the 43,499 unique (proteome) variants (alternatively,
62,957 genome variants) tried by SARS-CoV-2, only 6143 (alterna-
tively, 6914 genome variants) occurs at least 3 times, among
which, the top 200 proteome variants occur with the percentage
frequency above 0.04% (viz., found in at least 49 proteome
sequences) (Table S4 & Table S8). Alternatively, the top 200 gen-
ome variants have a percentage frequency above 0.03% (viz., found
in at least 37 genome sequences). Representative evolutionary
dynamics of different clades are shown in Fig. 5 and Figs. S6-S14.
Further, only 68 proteome variants occur at a PF above 0.1%, among
which, following variants appear at a moderate recurrence
(PF > 1%): PV-298 (clade-3d: Nsp2:T85I, Nsp12:P323L, Spike:
D614G, ORF3a protein:Q57H), PV-354 (clade-3e: Nsp12:P323L,
Spike:D614G, N protein:R203K; N protein:G204R), PV-22464
(clade-3f: Nsp12:P323L, Spike:L18F, Spike:A222V, Spike:D614G,
N protein:A220V, ORF10 protein:V30L), PV-14772 (clade-3e:
Nsp2:I120F, Nsp12:P323L, Spike:S477N, Spike:D614G, N protein:
R203K, N protein:G204R) and PV-52 (clade-3b: Nsp12:P323L,
Spike:D614G) (Fig. 5, Figs. S9, S11 & S12). These clearly indicate3871that the virus keeps evolving by trying different mutation combi-
nations. Among the remaining proteome variants, only 9 recur
above 0.5%. The evolutionary dynamics analysis of the top 3 vari-
ants further reveals the emergence of various sub-clades with
the inclusion of different mutations (Fig. 5, Figs. S8, S9, S10, S11
& S12). Interestingly, some of the combinations are localized to a
particular country. One such example is the acquisition of addi-
tional Nsp16:Q6L and Nsp7:S27L mutations in clade 3d which is
found to be specific to South Korea (PF = 0.22%) (Fig. 5). Similarly,
inclusion of Nsp2:I120F and Spike:S477N mutations into the
clade-3e (Nsp12:P323L, Spike:D614G, N protein:R203K, N pro-
tein:G204R which recurs at PF = 2.56%) leads to a sub-clade
(PF = 2.36%) which is specific to Australia (Fig. S11).
2.10. Emergence of 3e and 3d sub-clade variants with cocktail of
mutations and with increased transmissibility
As the world has again been thrown into chaos in December
2020 because of the independent emergence of two variants in
UK (VUI 202012/01, B.1.1.7) and South Africa (501Y.V2, B.1.351)
with an increased transmissibility [14,15]. Thus, a closer inspection
has been made on these variants despite their low recurrence until
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As noted earlier [16], both the variants have more than 10 amino
acid mutations, majorly in the spike protein (Fig. S15). While VUI
202012/01 (EPI_ISL_601443, September 20, 2020) has the highly
recurring Spike:D614G, Nsp12:P323L, N protein:G204R and N pro-
tein:R203K, 501Y.V2 (EPI_ISL_712081, September 8, 2020) has the
highly recurring Spike:D614G, Nsp12:P323L, Nsp2:T85I and ORF3a
protein:Q57H mutations. Thus, the former falls in the clade-3e and
the latter falls in the clade-3d. The key mutation that is common to
both the variants is N501Y and is found only in the low recurrence
until November 2020 (Fig. S15). Strikingly, the virus has tried these
mutation combinations in September 2020 itself in the respective
countries, but their role in increased transmissibility was unno-
ticed at that time. The data collected as on January 20, 2021 shows
that the former and the latter have disseminated across 35 and 10
countries respectively (Table S11). Thus, it is clear that these muta-
tion combinations are evolutionarily advantageous.2.11. Mutations in the SARS-CoV-2 vital motifs
To explore the impact of mutations in viral pathogenicity,
survival and host interaction, the presence of mutations in 22
key functional motifs of SARS-CoV-2 that are reported earlier
have been analyzed [17–22]. Only a few mutations, which occur
in a low to moderate percentage frequency, are seen in these
motifs or in their vicinity (Figs. S16-S18 & Table S12). For inci-
dence, among the N protein: S194L, N protein:S183Y and N pro-
tein:S188L mutations in SR motif, N protein:S194L is the only
moderately recurring mutation. Similarly, moderately recurring
H69- and V70- deletions in spike protein are seen in the vicinity
of GTNGTKR motif, which can jeopardize the ability of spike pro-
tein to interact with the receptors other than ACE2 [17]. The
other motifs are observed to be highly conserved (except the
presence of a few low recurring mutations, Figs. S16-S19) indi-
cating their importance in the survival of the virus.Fig. 6. Histogram illustrating the distribution of the clades in SARS-CoV-2 patients. Not
mild, recovered, hospitalized, severe and dead patients. Note that the CL-1a is highly di
clades are distributed in all kinds of patients.
38722.12. Dominance of clade-1a in asymptomatic and hospitalized
patients
Analysis of the limitedly available metadata (13,343 sequences,
viz., 1% of the total number of sequences considered in the current
study) indicates that the clade-1a (consists of Nsp6:L37F) is dom-
inant in asymptomatic and hospitalized patients [23] (Fig. 6 &
Table S13). Not surprisingly, sub-clades of D614G mutation are
prevalent in symptomatic (with patient status: undefined, mild
infection, severe infection and deceased) cases as D614G has taken
over the wild type.
Further analysis of metadata to derive the relationship between
the age and gender of the patients does not show any strong corre-
lation (Fig. S20 & Table S4). However, during post-lockdown per-
iod, the rate of female patients infected with SARS-CoV-2 have
become nearly equivalent to that of the male patients.3. Discussion
Complete global proteome/genome analysis of SARS-CoV-2
would help in tracking the mutations and their implications in host
immune evasion mechanisms, infectivity and mortality as well as
in assessing the effectiveness of the vaccines and drugs. An earlier
investigation from this laboratory [7] has reported that out of 2116
recurring mutations in the SARS-CoV-2 proteome, 7 are highly dis-
seminated during the early stage of the pandemic. Here, 125,746
complete SARS-CoV-2 proteome sequences collected worldwide
have been analyzed to understand their spread, sustainability
and their implication in viral pathogenicity and survival.
The mutation demographics indicate that only 0.14% of the total
sequences are wild-type (viz., the reference sequence published in
January 2020, [24]) although it has disseminated across the world
since its first occurrence in China in December 2019 before the
implementation of the international travel ban. In fact, only 20
countries have reported the wild-type sequence and its last
appearance has been seen in India in August 2020
(EPI_ISL_581502). This clearly indicates the high dynamics in the
SARS-CoV-2 proteome. Although SARS-CoV-2 has equipped with
a sophisticated RNA proofreading mechanism, overall 15,369
unique amino acids mutations (7326 positions) and 43,499 uniquee that the clade distribution is shown for asymptomatic, symptomatic (undefined),
stributed in asymptomatic patients and CL-1a, CL-2, CL-3b, CL-3c, CL-3d and CL-3e
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are different from the reference sequence) are found during
December 2019-November 2020. Nonetheless, only 7915 are
recurring (recurring at least in 3 sequences with a percentage fre-
quency of at least 0.002%) mutations involving 5146 positions sug-
gesting that they have a better evolutionary advantage compared
with the rest.
Intriguingly, among the 7915 recurring mutations, 10 are highly
recurring with an overall percentage frequency above 10%
(Fig. 1A). These mutations have their first incidences during the
pre-lockdown period (Fig. 2). While 6 of them are highly recurring
even from the pre-lockdown period (Spike:D614G, Nsp12:P323L, N
protein:R203K:G204R, ORF3a protein:Q57H, Nsp2:T85I), some of
them have picked up during the post-lockdown period indicating
that they are evolutionarily advantageous. Additionally, 51 muta-
tions are found to recur moderately (Fig. S2), among which, 45
and 6 have evolved during the pre- and post-lockdown periods
respectively and have sustained continuously. Among the 7854
less recurring mutations, 44% (3494) have emerged during the
pre-lockdown (till April 2020) period. Overall, the virus has identi-
fied 3973 amino acid positions out of 5146 (total number of recur-
ring mutation positions) as evolutionarily more advantageous than
the others, as they sustain along with high and/or moderate recur-
rent mutations during October 2020 or November 2020. Further,
the mutation persistence (See Materials and methods) indicates
that most of the mutations that have emerged in March 2020 are
highly persistent (Fig. 2B).
Strikingly, ORF3a protein:G251V (lineage B) that is having a
high recurrence during the pre-lockdown period has lost the evo-
lutionary race against Spike:D614G and Nsp12:P323L (lineage B)
and their combination is also evolutionarily disadvantageous
(Fig. 1B & 1C). Interestingly, ORF8 protein:L84S (lineage A) is also
in the declining phase with the surge of Spike:D614G and Nsp12:
P323L. Interestingly, only a rare occurrence of Spike:D614G and
Nsp12:P323L is seen in lineage A indicating their unfavorable coex-
istence with ORF8 protein:L84S (Fig. 1C). In support of this, the
recent emergence of a variant in Uganda which possesses ORF8
protein:L84S (lineage A.23.1) lacks Spike:D614Gmutation [5]. Very
interestingly, 42 mutations are found to be specific to lineage A
(Table S6).
With the existing mutations that are (majorly) acquired quite
early, the virus follows the tactics of having a cocktail of mutations
rather than evolving new mutations (Fig. 3C). This reflects in the
average number of mutations per sequence which is steadily
increasing every month (Fig. 3D). The most successful merging of
mutations is the Spike:D614G (clade-3a) and Nsp12:P323L
(clade-4) (along with 50UTR:C241T), leading to a subclade-3b.
Another notable example in line with this is the recently emerged
highly transmissible variants in UK (clade-3e) and South Africa
(clade-3d) with the cocktail of mutations. Interestingly, although
L18F (N-terminal domain of spike) is seen quite early when it
has occurred in clade 1a (EPI_ISL_417765, Iceland), its dissemina-
tion (found in 22 countries) has gained momentum only after July
2020 when the clade has started occurring along with clade 3b.
Similarly, merging of clades 1a and 3e (clade 1a_3e), clades 1a
and 3f (1a_3f) and clade-3f with trio mutation combinations (N
protein:A220V, ORF10 protein:V30L (synonymous mutation in
ORF10 stemloop:G29645T) and Spike:A222V) has evolutionary
advantages. Such merging of highly recurring mutations have led
to 5 major SARS-CoV-2 whole proteome clades (Fig. 4). Overall,
the cocktail of mutations (high and/or moderate and/or low recur-
rent) in the whole proteome has led to an increase in the number
of lineages every month (Fig. S4). Thus, the highest number of
unique variants (7561) have appeared in October 2020 (Fig. 3A,
Table S4 & S8). From the sequences that have been collected in
November 2020 and deposited in GISAID by December 10, 2020,38735140 unique proteome variants have been identified (Fig. 3A,
Table S4 & S8). Further, the early emergence of not only the major-
ity of high and moderate recurring mutations, but also, the major-
ity of low recurring mutations and their persistence (Fig. 2B (Left))
may still lead to several new cocktails of existing mutations. The
variants with such cocktails of mutations may have more infectiv-
ity etc.
Variant persistent analysis indicates that 199 variants occur in
at least 50 sequences. Nonetheless, there are 11 variants that are
found to occur in more than 500 sequences indicating that these
variants may be considered from the perspective of therapeutics
and diagnostics. Interestingly, the protein wise persistence analy-
ses (Fig. 2B and 3H) indicate that E protein may be more suitable
for drug and vaccine development and can also be used for diagno-
sis as it has a low relative persistence for mutation as well as for
variants.
The whole proteomic analysis of SARS-CoV-2 carried out here
indicates that the virus continues to evolve by following the tactics
of using the cocktail of beneficial mutations which have been
mostly picked up during the early stage of pandemic. This results
in the evolution of many divergent lineages under 5 major clades.
Nonetheless, very few mutation combinations have turned out to
be evolutionarily advantageous and have been sustained and dis-
seminated across several countries. The outcome of this study
may slightly differ since 64% of the total number of sequences used
in the current investigation are from UK (47%) and USA (17%). Fur-
ther only 19% of the sequences are contributed by six other coun-
tries (Australia (6.7%), Denmark (6.4%), Netherlands (1.6%),
Switzerland (1.5%), France (1.3%) and India (1.3%)) (Table S1) and
the remaining 17% are contributed by 113 countries. As the virus
keeps on examining the cocktail of mutations that can be evolu-
tionarily favorable, more variants may keep emerging through
the merging of different clades or through the inclusion of existing
mutations.4. Materials and methods
4.1. Data collection and creation of a local database
In order to analyze SARS-CoV-2 proteome collected across the
world, 180,385 complete high coverage sequences (viz., sequences
having less than 1% of undefined nucleotides) that were deposited
on or before December 10, 2020 and are sequenced on or before
November 30, 2020 were downloaded from the GISAID server
(https://www.gisaid.org/). The sequence dataset was further fil-
tered to discard the sequences with undefined nucleotides (‘‘N”)
in the coding region. The first published SARS-CoV-2 genome
sequence (Genbank ID: NC_045512.2) was used as the reference
sequence for both the amino acid and nucleotide mutation analy-
ses. The sequences with nucleotide insertions were separated out
from the dataset. Thus, 125,746 genomic sequences with no inser-
tions were further analyzed for any mutations in the 26 coding
regions [25]. Subsequently, the coding regions of 125,746
sequences were translated into individual proteins using the in-
house scripts and were subjected to mutational analysis. The in-
house bash and python scripts were written to translate the
SARS-CoV-2 genome into proteome and create a local repository
that contains month wise and country wise SARS-CoV-2 proteome.
The scripts were also used in the analysis of amino acid variations
in an automated fashion. Further, these sequences were segregated
based on the source country and the month of collection. Addition-
ally, the mutations in the non-coding regions were analyzed with-
out translation.
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The metadata file provided by GISAID was used for collecting
the information of source country, collection date, submission
date, GISAID clade name, and the age and gender of the host asso-
ciated with the viral sequence. These were stored in a local output
file along with the assigned protein variant (PV) number, the clade
names used in the current study and the mutations present in the
sequence (Table S8). It is noteworthy that only a small number of
sequences were found to have patient status information.
4.3. Mutation analysis
The amino acid mutation analyses were carried out as discussed
elsewhere [7]. They were categorized as high recurrent (HR, >10%),
moderate recurrent (MR, 1–10%) and low recurrent (LR, 0.002–1%)
mutations based on their recurrence in the 125,746 viral pro-
teomes. Note that the mutations that don’t occur in at least 3
sequences (viz., PF = 0.002%) were not considered. Further, the first
appearance and the country wise distribution of HR and MR muta-
tions were examined to understand their global dissemination. The
month wise changes in the functional motifs of SARS-CoV-2 were
analyzed through multiple sequence alignment (MSA) using CLUS-
TAL OMEGA [17,26]. The results were represented using Weblogo3
[27].
4.4. Proteome variant analysis
Comparative proteome analyses of 125,746 sequences with the
reference sequence were performed using Blast program [28] and
the results were analyzed using in-house scripts to identify the
mutations. Based on the presence of unique nucleotide mutations
with respect to the reference sequence, individual sequences were
assigned a genome variant number (NV). Similarly, protein variant
number (PV) was also assigned for SARS-CoV-2 whole proteome
variants. Further, based on the presence of HR mutation(s), the
variants were assigned a specific clade number (CL) (Fig. 4A)
[25]. In order to understand the evolution of SARS-CoV-2, the fre-
quency of occurrence of each variant was reported month wise
and country wise. The variants were further classified as new or
old based on their existence in the earlier months. This was to
identify whether a variant emerged for the first time in a month
or exists already.
4.5. Mutation or variant persistence analyses
A mutation or variant was considered to be persistent, if it had
emerged anytime during December 2019-Septemeber 2020 and
recurred in October 2020 or November 2020. The same methodol-
ogy was used to quantify the month wise and protein wise persis-
tence of mutations/variants.
4.6. Construction of phyloproteomic tree
The month wise phyloproteomic trees were created as
explained earlier [7] by considering the proteome sequences (viz.,
the non-coding regions were excluded) that were collected in a
particular month. Finally, the non-redundant whole proteomes
were alone used in the construction of the phyloproteomic tree
(Table S14). Initially, the selected sequences were subjected to
alignment using MAFFT [29] and then, the phyloproteomic trees
were constructed using the maximum likelihood method in IQ-
TREE software [30]. Itol tool [31] was used to visualize, analyze
and create the phylogram.
All the graphs were created using Microsoft Excel 16 and
Inkscape software was used for creating the Figures.3874Declaration of Competing Interest
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